ZA200208738B - Stabilized aqueous suspensions for parenteral use. - Google Patents

Stabilized aqueous suspensions for parenteral use.

Info

Publication number
ZA200208738B
ZA200208738B ZA200208738A ZA200208738A ZA200208738B ZA 200208738 B ZA200208738 B ZA 200208738B ZA 200208738 A ZA200208738 A ZA 200208738A ZA 200208738 A ZA200208738 A ZA 200208738A ZA 200208738 B ZA200208738 B ZA 200208738B
Authority
ZA
South Africa
Prior art keywords
aqueous suspensions
parenteral use
stabilized aqueous
stabilized
parenteral
Prior art date
Application number
ZA200208738A
Other languages
English (en)
Inventor
Giuseppe Colombo
Alessandro Martini
Lloyd E Fox
Original Assignee
Pharmacia Italia Spa
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia Spa, Upjohn Co filed Critical Pharmacia Italia Spa
Publication of ZA200208738B publication Critical patent/ZA200208738B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA200208738A 2000-05-15 2002-10-29 Stabilized aqueous suspensions for parenteral use. ZA200208738B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/571,395 US6495534B2 (en) 2000-05-15 2000-05-15 Stabilized aqueous suspensions for parenteral use

Publications (1)

Publication Number Publication Date
ZA200208738B true ZA200208738B (en) 2003-10-29

Family

ID=24283530

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200208738A ZA200208738B (en) 2000-05-15 2002-10-29 Stabilized aqueous suspensions for parenteral use.

Country Status (30)

Country Link
US (3) US6495534B2 (enExample)
EP (1) EP1282402B1 (enExample)
JP (1) JP4205341B2 (enExample)
KR (1) KR100828957B1 (enExample)
CN (1) CN100473376C (enExample)
AR (3) AR029924A1 (enExample)
AT (1) ATE313316T1 (enExample)
AU (2) AU6737101A (enExample)
BR (1) BR0110841A (enExample)
CA (1) CA2409059C (enExample)
CZ (1) CZ303872B6 (enExample)
DE (1) DE60116084T2 (enExample)
DK (1) DK1282402T3 (enExample)
EA (1) EA007682B1 (enExample)
EE (1) EE05376B1 (enExample)
ES (1) ES2254443T3 (enExample)
HK (1) HK1054194B (enExample)
HU (1) HU229800B1 (enExample)
IL (2) IL152537A (enExample)
IN (1) IN224279B (enExample)
MX (1) MXPA02011195A (enExample)
NO (1) NO332215B1 (enExample)
NZ (1) NZ522324A (enExample)
PE (1) PE20011322A1 (enExample)
PL (1) PL203075B1 (enExample)
SI (1) SI1282402T1 (enExample)
SK (1) SK287641B6 (enExample)
TW (1) TWI256310B (enExample)
WO (1) WO2001087266A1 (enExample)
ZA (1) ZA200208738B (enExample)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495534B2 (en) * 2000-05-15 2002-12-17 Pharmacia & Upjohn Spa Stabilized aqueous suspensions for parenteral use
US7482116B2 (en) 2002-06-07 2009-01-27 Dna Genotek Inc. Compositions and methods for obtaining nucleic acids from sputum
ATE345277T1 (de) 2002-08-21 2006-12-15 Pharmacia Corp Injizierbare pharmazeutische suspension in einer phiole mit zwei kammern
US20050054716A1 (en) * 2002-11-08 2005-03-10 Gogate Uday Shankar Pharmaceutical compositions and methods of using taxane derivatives
CN1767815A (zh) * 2003-03-31 2006-05-03 阿尔萨公司 非水单相载体和使用这类载体的制剂
EP2617411A1 (en) * 2003-09-03 2013-07-24 Miscon Trading S.A. Methods for the Treatment of Endometriosis
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
US20050106214A1 (en) * 2003-11-14 2005-05-19 Guohua Chen Excipients in drug delivery vehicles
CA2581076A1 (en) * 2004-09-14 2006-03-23 Molecular Therapeutics, Inc. D-methionine formulation with improved biopharmaceutical properties
US20060204588A1 (en) * 2005-03-10 2006-09-14 Elan Pharma International Limited Formulations of a nanoparticulate finasteride, dutasteride or tamsulosin hydrochloride, and mixtures thereof
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
US20070154546A1 (en) * 2005-12-30 2007-07-05 Zhang Jack Y Sustained release pharmaceutical compositions
EP1993598A2 (en) * 2006-02-15 2008-11-26 Tika Läkemedel AB Methods of manufacturing corticosteroid solutions
TW200806317A (en) * 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
JP5371180B2 (ja) * 2006-06-15 2013-12-18 日立コンシューマエレクトロニクス株式会社 投写型映像表示装置
US7687516B2 (en) * 2006-09-27 2010-03-30 Eagle Pharmaceuticals, Inc. Alcohol free formulation of argatroban
JP5624766B2 (ja) * 2006-09-27 2014-11-12 イーグル・ファーマシューティカルズ・インコーポレーテッド アルコールを含まないアルガトロバン製剤
US20100076019A1 (en) * 2006-10-11 2010-03-25 Eagle Pharmaceuticals, Inc. Alcohol free formulation of argatroban
GB0625962D0 (en) * 2006-12-23 2007-02-07 Renovo Ltd Medicaments and methods for wound healing
EP2185112A4 (en) * 2007-08-21 2012-01-18 Harbor Biosciences Inc Stabilized therapeutic compositions and formulations
US8287729B2 (en) * 2008-04-28 2012-10-16 California Polytechnic Corporation Field water purification system
GB0813628D0 (en) * 2008-07-25 2008-09-03 Arrow Int Ltd Stable coated anti-cancer agent
UY33103A (es) * 2009-12-15 2011-07-29 Techsphere S A De C V Formulacion farmaceutica parenteral en suspension, de liberacion sostenida, en dosis baja y ultra baja, en terapia hormonal en el sindrome climaterico
BR112013032629A2 (pt) 2011-06-19 2017-08-01 Abogen Inc dispositivos, soluções e métodos para coletamento de amostra
EP3936133A1 (en) 2011-11-23 2022-01-12 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
UA74095U (ru) * 2012-07-20 2012-10-10 Николай Иванович Гуменюк Препарат для лечения туберкулеза
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9649353B2 (en) 2013-09-17 2017-05-16 Terapio Corporation Methods of preventing or treating mucositis by administering RLIP76
CN104706578B (zh) * 2013-12-14 2019-04-23 天津金耀集团有限公司 一种醋酸甲泼尼龙混悬注射液组合物的制备方法
AR100562A1 (es) 2014-05-22 2016-10-12 Therapeuticsmd Inc Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
US9907449B2 (en) 2015-03-16 2018-03-06 Irobot Corporation Autonomous floor cleaning with a removable pad
US9265396B1 (en) 2015-03-16 2016-02-23 Irobot Corporation Autonomous floor cleaning with removable pad
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017149492A1 (en) * 2016-03-02 2017-09-08 Teva Pharmaceutical Industries Ltd. Medroxyprogesterone acetate injectable compositions and methods of use
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
RU2018133932A (ru) 2016-04-01 2020-05-12 Терапьютиксмд, Инк. Фармацевтическая композиция стероидного гормона
IL285928B2 (en) * 2016-05-06 2025-06-01 Eagle Pharmaceuticals Inc Fulvestrant formulations and methods of their use
WO2019094650A1 (en) * 2017-11-08 2019-05-16 Eagle Pharmaceuticals, Inc Fulvestrant formulations and methods of their use
US11590077B2 (en) * 2016-05-06 2023-02-28 Eagle Pharmaceuticals, Inc. Fulvestrant formulations and methods of their use
PE20200336A1 (es) 2017-07-14 2020-02-14 Janssen Pharmaceutica Nv Formulaciones a largo plazo
MX2020002606A (es) * 2017-09-07 2020-10-05 Teva Pharma Composiciones inyectables de acetato de medroxiprogesterona y metodos de uso.
EP3678637A1 (en) * 2017-09-07 2020-07-15 Teva Pharmaceutical Industries Ltd. Medroxyprogesterone acetate injectable compositions and methods of use
IL275394B2 (en) * 2018-01-11 2024-11-01 Meritage Pharma Inc Stable corticosteroid compositions
EP3846777B1 (en) 2018-09-07 2025-12-10 Family Health International Medroxyprogesterone acetate injectable compositions and methods of use
US10544923B1 (en) 2018-11-06 2020-01-28 Verifone, Inc. Devices and methods for optical-based tamper detection using variable light characteristics
MY207327A (en) 2018-11-20 2025-02-19 Spectrum Solutions Llc Sample collection system including sealing cap and valve
IT201900002857A1 (it) * 2019-02-27 2020-08-27 Ntc S R L Procedimento di riempimento di contenitori con una polvere
US11701094B2 (en) 2019-06-20 2023-07-18 Spectrum Solutions L.L.C. Sample collection system including valve and plug assemblies
WO2021146215A1 (en) 2020-01-13 2021-07-22 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
KR20230145053A (ko) 2021-01-12 2023-10-17 듀렉트 코퍼레이션 지속 방출 약물 전달 시스템 및 관련 방법
TW202239408A (zh) * 2021-01-29 2022-10-16 瑞士商艾克泰聯製藥有限公司 包含二苯基吡𠯤衍生物的醫藥組成物
US20240237929A1 (en) * 2021-05-19 2024-07-18 Acies Medical Llc Point-of-use calibration system for iron ion detection system

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2861920A (en) * 1954-05-04 1958-11-25 Upjohn Co Therapeutic suspensions of steroids containing pvp and/or pva
JPS5831210B2 (ja) * 1973-04-09 1983-07-05 武田薬品工業株式会社 アンテイナスイセイケンダクエキノセイゾウホウ
US4038389A (en) * 1975-05-07 1977-07-26 The Upjohn Company Medroxyprogesterone acetate compositions
US4154820A (en) * 1976-02-23 1979-05-15 Akzona Incorporated Compositions containing alkali metal sulfate salts of conjugated estrogens and antioxidants as stabilizers
JP2577744B2 (ja) 1986-07-18 1997-02-05 中外製薬株式会社 安定な顆粒球コロニ−刺激因子含有製剤
ES2062310T3 (es) 1989-12-06 1994-12-16 Akzo Nv Un procedimiento para fabricar un preparado farmaceutico acuoso estabilizado.
US5208261A (en) * 1989-12-06 1993-05-04 Akzo N.V. Stabilized solutions of psychotropic agents
JPH0597671A (ja) 1991-10-04 1993-04-20 Sumitomo Pharmaceut Co Ltd 注射用凍結乾燥製剤
CA2120197A1 (en) 1993-04-02 1994-10-03 Kenji Endo Stable aqueous dispersions containing liposomes
JP3862295B2 (ja) * 1993-09-30 2006-12-27 独立行政法人理化学研究所 抗肥満剤
US5540930A (en) * 1993-10-25 1996-07-30 Pharmos Corporation Suspension of loteprednol etabonate for ear, eye, or nose treatment
JP3543144B2 (ja) 1995-03-11 2004-07-14 国際試薬株式会社 臨床検査用製剤
US5780431A (en) 1996-09-20 1998-07-14 Neurobiological Technologies, Inc. Pharmaceutical formulations of corticotropin releasing factor having improved stability in liquid form
CN1142940C (zh) 1996-10-04 2004-03-24 安姆根有限公司 含有mpl配体的药物组合物
US5773432A (en) * 1996-10-30 1998-06-30 Schering Aktiengesellschaft Method for lowering plasma levels of lipoprotein(a)
US5880116A (en) * 1996-12-13 1999-03-09 Neurocal International Use of celastrol to treat alzheimer's disease
JP3748970B2 (ja) 1997-01-31 2006-02-22 電気化学工業株式会社 ヒアルロン酸ナトリウム含有水溶液
KR100508227B1 (ko) 1997-03-14 2006-03-23 센주 세이야꾸 가부시키가이샤 로테프레드놀에타보네이트수성현탁액
DE59811910D1 (de) 1997-09-23 2004-10-07 Rentschler Biotech Gmbh Flüssige Interferon-Beta Formulierungen
US5968918A (en) * 1997-10-17 1999-10-19 Kanda; Iwao Method for the prevention of coronary artery spasm
US5972921A (en) * 1997-12-12 1999-10-26 Hormos Medical Oy Ltd. Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men
DE69913116T2 (de) 1998-04-02 2004-06-03 Akzo Nobel N.V. Orale flüssige lösung enthaltend das antidepressivum mirtazapine
WO2001024814A1 (en) 1999-10-04 2001-04-12 Chiron Corporation Stabilized liquid polypeptide-containing pharmaceutical compositions
US6495534B2 (en) * 2000-05-15 2002-12-17 Pharmacia & Upjohn Spa Stabilized aqueous suspensions for parenteral use

Also Published As

Publication number Publication date
NO20025431L (no) 2003-01-13
US20020115645A1 (en) 2002-08-22
MXPA02011195A (es) 2003-03-10
TWI256310B (en) 2006-06-11
AU2001267371B2 (en) 2006-01-05
HU229800B1 (en) 2014-07-28
CN1429101A (zh) 2003-07-09
AR029924A1 (es) 2003-07-23
EE200200631A (et) 2004-04-15
HUP0302021A2 (hu) 2003-09-29
DK1282402T3 (da) 2006-05-08
AU6737101A (en) 2001-11-26
KR100828957B1 (ko) 2008-05-13
CA2409059A1 (en) 2001-11-22
EP1282402A1 (en) 2003-02-12
HK1054194B (zh) 2010-02-12
EA007682B1 (ru) 2006-12-29
WO2001087266A1 (en) 2001-11-22
AR111695A2 (es) 2019-08-07
NZ522324A (en) 2005-02-25
NO332215B1 (no) 2012-07-30
AR098830A2 (es) 2016-06-15
CA2409059C (en) 2006-04-18
DE60116084T2 (de) 2006-08-17
KR20030020280A (ko) 2003-03-08
CZ303872B6 (cs) 2013-06-05
IL165888A0 (en) 2006-01-15
SK287641B6 (sk) 2011-05-06
SK15982002A3 (sk) 2003-05-02
US20030130245A1 (en) 2003-07-10
CN100473376C (zh) 2009-04-01
HK1054194A1 (zh) 2003-11-21
JP4205341B2 (ja) 2009-01-07
PE20011322A1 (es) 2002-01-10
IL152537A (en) 2007-06-17
US6495534B2 (en) 2002-12-17
BR0110841A (pt) 2003-03-11
SI1282402T1 (sl) 2006-04-30
US20030114430A1 (en) 2003-06-19
CZ20023750A3 (cs) 2003-03-12
DE60116084D1 (de) 2006-01-26
PL203075B1 (pl) 2009-08-31
NO20025431D0 (no) 2002-11-13
PL365793A1 (en) 2005-01-10
IN224279B (enExample) 2005-02-25
EP1282402B1 (en) 2005-12-21
ATE313316T1 (de) 2006-01-15
IL152537A0 (en) 2003-05-29
ES2254443T3 (es) 2006-06-16
EA200201208A1 (ru) 2003-04-24
EE05376B1 (et) 2011-02-15
HUP0302021A3 (en) 2011-03-28
JP2003533467A (ja) 2003-11-11

Similar Documents

Publication Publication Date Title
ZA200208738B (en) Stabilized aqueous suspensions for parenteral use.
ZA200207331B (en) Ethylenediamine derivatives.
MXPA03002269A (es) Derivados de purina.
MXPA03005270A (es) Derivados de piperazina.
MXPA03002410A (es) 4-amino-quinazolinas.
MXPA03000078A (es) Derivados de purina.
MXPA03005445A (es) Barra colectora 12c para aislar los circuitos integrados seleccionados para una comunicacion rapida de barra colectora 12c.
MXPA03002256A (es) Factor viii modificado.
MXPA01011516A (es) Incinerador de pared radiante de bajo nox.
ZA200007669B (en) Insert.
EG23262A (en) Delta -pyrrolines.
MXPA01010764A (es) Ensamble de quemador de emisiones bajas en nox y metodo para reducir el contenido de nox de gas de combustion de alto horno.
MXPA03008140A (es) Amidas de acido benzofuran-2-carboxilico sustituidas.
MXPA03001591A (es) Derivados y analogos de 10-aril-11-h-benzo(b) fluorena para uso medicinal.
MXPA03001877A (es) 2-guanidin-4-arilquinazolinas.
MXPA03002668A (es) Guanidinas de sulfonilo.
MXPA03004453A (es) Derivados de pirimidina.
ZA200205482B (en) Aminosulfonylbiphenyl derivatives.
ZA200206151B (en) Substituted amionomethyl-phenyl-cyclohexane derivatives.
MXPA03005714A (es) Sulfamidotienopirimidinas.
MXPA03002411A (es) 4-amino-quinazolinas.
HUP0300562A3 (en) Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the
MXPA03002737A (es) Derivados sustituidos de 1-aminobutan-3-ol.
ZA200206150B (en) Aminomethyl-phenyl-cyclohexanone derivatives.
MXPA03005494A (es) Benzoilpiridazinas.